Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
EXELIXIS, INC. President and CEO Michael Morrissey reported multiple equity transactions in company common stock. He exercised an option for 494,700 shares on February 13, 2026 at a stated exercise price of $21.31 per share, increasing his direct holdings.
To cover the option exercise price and related taxes, 369,606 shares were withheld at $43.92 per share, and a further 120,390 shares were withheld on February 15, 2026 to satisfy tax liabilities after performance-based restricted stock units vested. Morrissey also made bona fide gifts totaling 501,472 shares over February 17–18, 2026, transferring shares to the Morrissey Family Trust, which holds shares as trustees.
A footnote states that 1,454,115 shares of common stock will be issued upon vesting of previously granted RSUs and performance stock units, each representing the right to receive one share of common stock.
Exelixis director Sue Gail Eckhardt reported an open-market sale of 3,856 shares of common stock on February 13, 2026 at a weighted average price of $43.79 per share. The transaction was executed under a prearranged Rule 10b5-1 trading plan adopted on November 11, 2025. After this sale, she beneficially owns 17,524 shares, including shares that will be issued upon vesting of restricted stock units.
EXELIXIS, INC. executive Dana Aftab, EVP of Research and Development, reported two tax-related share dispositions. On February 15, 2026, a total of 26,485 and 12,720 shares of common stock were withheld at $43.92 per share to cover taxes due upon vesting of performance-based restricted stock units granted on March 4, 2022 and restricted stock units granted on January 5, 2023. These are tax-withholding dispositions, not open-market sales. After these transactions, Aftab directly holds 693,897 shares of common stock, which include 414,043 shares underlying restricted stock units and performance stock units granted on March 31, 2025. In addition, there are 5,835 shares held indirectly through the Exelixis 401(k) Plan as of February 13, 2026.
Exelixis, Inc. director Bob Oliver reported mixed activity in company stock. On February 13, 2026, he sold 9,088 shares of common stock in an open-market transaction at $43.61 per share and separately sold 21,162 shares at a weighted average price of $43.90 per share, with individual trades between $43.90 and $43.96 as noted in a footnote.
On the same date, he exercised an option for 9,088 shares of common stock, recorded as both a derivative exercise and an acquisition of common shares at an exercise price of $19.28 per share. A footnote states this option originally covered 36,353 shares and became fully exercisable on May 31, 2023. Another footnote notes 18,900 restricted stock units that will convert into common shares upon vesting.
EXELIXIS, INC. senior vice president and general counsel Brenda Hefti reported insider transactions in company common stock. She sold 18,669 shares in an open-market sale at an average price of $44.01 per share under a pre-arranged Rule 10b5-1 trading plan. Separately, 5,430 shares were withheld by the company to cover taxes due on the vesting of performance-based restricted stock units. After these transactions, she continued to hold a substantial direct equity position, along with additional restricted stock units, performance stock units expected to deliver 95,956 shares upon vesting, and 5,527 shares held indirectly through the company’s 401(k) plan.
Insider sale notice: A reporting person submitted a Form 144 indicating a proposed sale of 64,117 shares on 02/18/2026. The filing also reports prior sales of 42,422 shares on 02/17/2026 for $1,880,439.99.
EXEL reports a Form 144 notice proposing sales of common stock. The notice names Morgan Stanley Smith Barney LLC as the broker-dealer and includes numeric entries such as 821,663.76 and 259,708,689 alongside an 02/18/2026 date. The filing also lists two performance share lines dated 01/16/2025 and 02/15/2026.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the planned sale of 99,574 Common shares with an aggregate value of $4,382,506.87 on 02/18/2026. The notice lists prior issuances and exercises of Common stock on several dates, including 03/29/2021, 04/01/2019, 05/21/2021, 05/23/2020, and 04/04/2022.
A shareholder of Exelixis filed a notice to sell 42,422 shares of common stock under Rule 144. The shares are expected to be sold on or about 02/17/2026 through NASDAQ, with Morgan Stanley Smith Barney LLC listed as the broker.
These shares were acquired on 02/17/2026 through a stock option exercise from the issuer, paid for in cash, and have an indicated aggregate market value of $1,880,439.99. The filing notes that total shares outstanding are 259,708,689 for context.
A company insider has filed a Form 144 indicating an intent to sell 30,617 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,337,035.20. The shares, classified as performance shares, were acquired from the issuer on 02/15/2026, with the same date listed for payment. The approximate sale date is 02/17/2026 on the NASDAQ market. Over the prior three months, Christopher J. Senner sold 34,278 common shares for $1,473,964.28. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer.